1095-P: Glycemic Trend in Metropolitan versus Non-metropolitan Cities of India: One-Year Results of LANDMARC

Abstract

Data on glycemic status in patients with diabetes from metropolitan and non-metropolitan cities of India are unavailable. Hence, glycemic trend was evaluated among patients from metropolitan versus non-metropolitan cities during the first year of LANDMARC trial (a 3-year nationwide prospective observational study; CTRI/2017/05/008452). A total of 6236 patients with type 2 diabetes (T2D) taking ≥2 antihyperglycemic medications (with/without glycemic control) were enrolled, of which 5654 completed 1-year follow-up visit. The age, T2D duration, baseline A1C were comparable across patients from metropolitan and non-metropolitan cities (Table). At 1-year, a decrease in all glycemic parameters was noted. However, the difference in fall in A1C from baseline between patients from metropolitan and non-metropolitan cities was not significant (mean [95% CI]: -0.5% [-0.5, -0.4] vs. -0.5% [-0.5, -0.4]; p=0.86). For FPG and PPG, the difference in change from baseline between the two groups was also not significant (p>0.05) (Table). In the first-year, patients from both metropolitan and non-metropolitan cities showed marked improvement in glycemic status with similar trends for change in glycemic parameters. These results help compare the longitudinal glycemic patterns among patients with T2D in metropolitan and non-metropolitan cities across India.View largeDownload slideView largeDownload slide DisclosureA. Unnikrishnan: Advisory Panel; Self; Sanofi-Aventis, Other Relationship; Self; Novo Nordisk A/S, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes. R. Ghosh: Employee; Self; Sanofi. S. Krishnan: Employee; Self; Sanofi. A. Nair: Employee; Self; Sanofi. S. Mohanasundaram: Employee; Self; Sanofi. S. K. Menon: Employee; Self; Sanofi. V. Salvi: Employee; Self; Sanofi. D. Chodankar: Employee; Self; Sanofi. C. Trivedi: None. S. Wangnoo: None. A. H. Zargar: None. A. K. Das: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Roche Pharma, Sanofi. N. Rais: None. S. Joshi: Advisory Panel; Self; Abbott, AstraZeneca, Biocon, Franco Indian, Glenmark, Lupin, Marico, Roche, Twinhealth, Zydus, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Sanofi, Serdia Pharmaceuticals (India) Pvt. Ltd. A. Mithal: Advisory Panel; Self; Eris Lifesciences Limited, Consultant; Self; Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals, Inc., USV Private Limited, Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Novo Nordisk, Sanofi. S. Kalra: Speaker’s Bureau; Self; Eli Lilly and Company, Novo Nordisk, Sanofi. K. Kumar: Advisory Panel; Self; Sanofi-Aventis. H. Thacker: None. B. Sethi: None. S. Chowdhury: None.FundingSanofi